Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upM. Dreyling, Marco Ladetto, Elı́as Campo et al.|Annals of Oncology|2017Cited by 736
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Ewa Lech‐Marańda et al.|The Lancet|2021Cited by 456
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)Michele Ghielmini, Markus Raderer, Umberto Vitolo et al.|Annals of Oncology|2012Cited by 218
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trialAndrew D. Zelenetz, Franck Morschhauser, Gilles Salles et al.|Blood|2019Cited by 136
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upM. Dreyling, Marco Ladetto, Carsten Geisler et al.|Annals of Oncology|2014Cited by 136